Skip to main content
Top
Published in: Journal of Neurology 5/2012

01-05-2012 | Review

A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis

Authors: Christopher Eckstein, Shiv Saidha, Michael Levy

Published in: Journal of Neurology | Issue 5/2012

Login to get access

Abstract

Although multiple sclerosis (MS) is the most common demyelinating disorder of the central nervous system (CNS), it lacks any definitive diagnostic test. Instead, diagnosis of MS primarily depends upon clinical criteria, supported by abnormalities characteristic of MS on para-clinical investigations including magnetic resonance imaging of the brain and spine, in the absence of an alternative explanation for underlying neurologic symptoms. While many of the potential disorders that may mimic MS in routine clinical practice are either extremely rare, or associated with specific and characteristic distinguishing diagnostic features, some inflammatory demyelinating disorders of the CNS may be particularly challenging to distinguish from MS, especially during initial presentation. In particular, acute disseminated encephalomyelitis, neuromyelitis optica, and idiopathic transverse myelitis may closely resemble MS, impeding prompt and accurate diagnosis. In this review, we describe the clinical features, diagnosis, pathology, and treatment of these other CNS demyelinating disorders. In addition, we review relevant features of other CNS inflammatory disorders that may mimic MS, including Sjögren’s syndrome, systemic lupus erythematosus, Behçet’s disease, and primary CNS vasculitis.
Literature
1.
go back to reference Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.1002/ana.22366 PubMedCrossRef Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.​1002/​ana.​22366 PubMedCrossRef
2.
go back to reference Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14(9):1157–1174. doi:10.1177/1352458508096878 PubMedCrossRef Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14(9):1157–1174. doi:10.​1177/​1352458508096878​ PubMedCrossRef
3.
go back to reference de Seze J (2007) Multiple sclerosis: clinical aspects, acute disseminated encephalomyelitis, neuromyelitis optica and other inflammatory variants. Rev Neurol (Paris) 163(6–7):647–650CrossRef de Seze J (2007) Multiple sclerosis: clinical aspects, acute disseminated encephalomyelitis, neuromyelitis optica and other inflammatory variants. Rev Neurol (Paris) 163(6–7):647–650CrossRef
4.
go back to reference Torisu H, Kira R, Ishizaki Y, Sanefuji M, Yamaguchi Y, Yasumoto S, Murakami Y, Shimono M, Nagamitsu S, Masuzaki M, Amamoto M, Kondo R, Uozumi T, Aibe M, Gondo K, Hanai T, Hirose S, Matsuishi T, Shirahata A, Mitsudome A, Hara T (2010) Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 32(6):454–462. doi:10.1016/j.braindev.2009.10.006 PubMedCrossRef Torisu H, Kira R, Ishizaki Y, Sanefuji M, Yamaguchi Y, Yasumoto S, Murakami Y, Shimono M, Nagamitsu S, Masuzaki M, Amamoto M, Kondo R, Uozumi T, Aibe M, Gondo K, Hanai T, Hirose S, Matsuishi T, Shirahata A, Mitsudome A, Hara T (2010) Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 32(6):454–462. doi:10.​1016/​j.​braindev.​2009.​10.​006 PubMedCrossRef
5.
go back to reference Tselis A, Lisak R (2005) Acute disseminated encephalomyelitis. In: Antel JP, Birnbaum G, Hartung HP, Vincent A (eds) Clinical neuroimmunology. Oxford University Press, New York, pp 147–171 Tselis A, Lisak R (2005) Acute disseminated encephalomyelitis. In: Antel JP, Birnbaum G, Hartung HP, Vincent A (eds) Clinical neuroimmunology. Oxford University Press, New York, pp 147–171
9.
go back to reference Kuker W, Ruff J, Gaertner S, Mehnert F, Mader I, Nagele T (2004) Modern MRI tools for the characterization of acute demyelinating lesions: value of chemical shift and diffusion-weighted imaging. Neuroradiology 46(6):421–426. doi:10.1007/s00234-004-1203-5 PubMedCrossRef Kuker W, Ruff J, Gaertner S, Mehnert F, Mader I, Nagele T (2004) Modern MRI tools for the characterization of acute demyelinating lesions: value of chemical shift and diffusion-weighted imaging. Neuroradiology 46(6):421–426. doi:10.​1007/​s00234-004-1203-5 PubMedCrossRef
11.
go back to reference Ben Sira L, Miller E, Artzi M, Fattal-Valevski A, Constantini S, Ben Bashat D (2010) 1H-MRS for the diagnosis of acute disseminated encephalomyelitis: insight into the acute-disease stage. Pediatr Radiol 40(1):106–113. doi:10.1007/s00247-009-1372-9 PubMedCrossRef Ben Sira L, Miller E, Artzi M, Fattal-Valevski A, Constantini S, Ben Bashat D (2010) 1H-MRS for the diagnosis of acute disseminated encephalomyelitis: insight into the acute-disease stage. Pediatr Radiol 40(1):106–113. doi:10.​1007/​s00247-009-1372-9 PubMedCrossRef
13.
go back to reference Franciotta D, Columba-Cabezas S, Andreoni L, Ravaglia S, Jarius S, Romagnolo S, Tavazzi E, Bergamaschi R, Zardini E, Aloisi F, Marchioni E (2008) Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol 200(1–2):125–128. doi:10.1016/j.jneuroim.2008.06.004 PubMedCrossRef Franciotta D, Columba-Cabezas S, Andreoni L, Ravaglia S, Jarius S, Romagnolo S, Tavazzi E, Bergamaschi R, Zardini E, Aloisi F, Marchioni E (2008) Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol 200(1–2):125–128. doi:10.​1016/​j.​jneuroim.​2008.​06.​004 PubMedCrossRef
15.
go back to reference Lalive PH, Hausler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, Schroeter M, Hartung HP, Kieseier BC, Menge T (2011) Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 17(3):297–302. doi:10.1177/1352458510389220 PubMedCrossRef Lalive PH, Hausler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, Schroeter M, Hartung HP, Kieseier BC, Menge T (2011) Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 17(3):297–302. doi:10.​1177/​1352458510389220​ PubMedCrossRef
17.
go back to reference Rodriguez M, Powell H, Lampert W (1983) Demyelination and leukodystrophy in the clinical neurosciences. In: Rosenberg R, Schoclet S (eds) Neuropathology, vol III. Churchill Livinstone, New York, pp 419–443 Rodriguez M, Powell H, Lampert W (1983) Demyelination and leukodystrophy in the clinical neurosciences. In: Rosenberg R, Schoclet S (eds) Neuropathology, vol III. Churchill Livinstone, New York, pp 419–443
18.
go back to reference Stricker RB, Miller RG, Kiprov DD (1992) Role of plasmapheresis in acute disseminated (post-infectious) encephalomyelitis. J Clin Apher 7(4):173–179PubMedCrossRef Stricker RB, Miller RG, Kiprov DD (1992) Role of plasmapheresis in acute disseminated (post-infectious) encephalomyelitis. J Clin Apher 7(4):173–179PubMedCrossRef
19.
go back to reference Straub J, Chofflon M, Delavelle J (1997) Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery. Neurology 49(4):1145–1147PubMedCrossRef Straub J, Chofflon M, Delavelle J (1997) Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery. Neurology 49(4):1145–1147PubMedCrossRef
20.
go back to reference Dalakas MC (1998) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51(6 Suppl 5):S2–S8PubMedCrossRef Dalakas MC (1998) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51(6 Suppl 5):S2–S8PubMedCrossRef
21.
go back to reference Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G (2000) Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 54(6):1370–1372PubMedCrossRef Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G (2000) Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 54(6):1370–1372PubMedCrossRef
22.
go back to reference Kleiman M, Brunquell P (1995) Acute disseminated encephalomyelitis: response to intravenous immunoglobulin. J Child Neurol 10(6):481–483PubMedCrossRef Kleiman M, Brunquell P (1995) Acute disseminated encephalomyelitis: response to intravenous immunoglobulin. J Child Neurol 10(6):481–483PubMedCrossRef
23.
go back to reference Bala B, Banwell B (2010) Cognitive and behavioural outcomes in individuals with a history of childhood acute disseminated encephalomyelitis. 62nd Annual Meeting, American Academy of Neurology, Toronto, pp IN2-2.005 Bala B, Banwell B (2010) Cognitive and behavioural outcomes in individuals with a history of childhood acute disseminated encephalomyelitis. 62nd Annual Meeting, American Academy of Neurology, Toronto, pp IN2-2.005
24.
go back to reference Donmez FY, Aslan H, Coskun M (2009) Evaluation of possible prognostic factors of fulminant acute disseminated encephalomyelitis (ADEM) on magnetic resonance imaging with fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted imaging. Acta Radiol 50(3):334–339. doi:10.1080/02841850902736617 PubMedCrossRef Donmez FY, Aslan H, Coskun M (2009) Evaluation of possible prognostic factors of fulminant acute disseminated encephalomyelitis (ADEM) on magnetic resonance imaging with fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted imaging. Acta Radiol 50(3):334–339. doi:10.​1080/​0284185090273661​7 PubMedCrossRef
26.
go back to reference Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B (2001) Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 56(10):1313–1318PubMedCrossRef Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B (2001) Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 56(10):1313–1318PubMedCrossRef
30.
go back to reference Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114PubMedCrossRef Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114PubMedCrossRef
31.
go back to reference Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, Mancardi L, Gallo P, Filippi M, Zaffaroni M, Comi G (2004) Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol 251(1):47–52. doi:10.1007/s00415-004-0271-0 PubMedCrossRef Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, Mancardi L, Gallo P, Filippi M, Zaffaroni M, Comi G (2004) Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol 251(1):47–52. doi:10.​1007/​s00415-004-0271-0 PubMedCrossRef
35.
go back to reference Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112. doi:10.1016/S0140-6736(04)17551-X PubMedCrossRef Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112. doi:10.​1016/​S0140-6736(04)17551-X PubMedCrossRef
36.
go back to reference Eckstein C, Syc S, Saidha S (2011) Differential diagnosis of longitudinally extensive transverse myelitis in adults. Eur Neurol J 3(1):27–39 Eckstein C, Syc S, Saidha S (2011) Differential diagnosis of longitudinally extensive transverse myelitis in adults. Eur Neurol J 3(1):27–39
37.
go back to reference Matsuoka T, Matsushita T, Osoegawa M, Ochi H, Kawano Y, Mihara F, Ohyagi Y, Kira J (2008) Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings. J Neurol Sci 266(1–2):115–125PubMedCrossRef Matsuoka T, Matsushita T, Osoegawa M, Ochi H, Kawano Y, Mihara F, Ohyagi Y, Kira J (2008) Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings. J Neurol Sci 266(1–2):115–125PubMedCrossRef
38.
39.
go back to reference Nakashima I, Fujihara K, Miyazawa I, Misu T, Narikawa K, Nakamura M, Watanabe S, Takahashi T, Nishiyama S, Shiga Y, Sato S, Weinshenker BG, Itoyama Y (2006) Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 77(9):1073–1075. doi:10.1136/jnnp.2005.080390 PubMedCrossRef Nakashima I, Fujihara K, Miyazawa I, Misu T, Narikawa K, Nakamura M, Watanabe S, Takahashi T, Nishiyama S, Shiga Y, Sato S, Weinshenker BG, Itoyama Y (2006) Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 77(9):1073–1075. doi:10.​1136/​jnnp.​2005.​080390 PubMedCrossRef
40.
go back to reference Weinshenker BG, Wingerchuk DM, Nakashima I, Fujihara K, Lennon VA (2006) OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 5(2):110–111PubMedCrossRef Weinshenker BG, Wingerchuk DM, Nakashima I, Fujihara K, Lennon VA (2006) OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 5(2):110–111PubMedCrossRef
41.
go back to reference Kira J (2008) Neuromyelitis optica and Asian phenotype of multiple sclerosis. Ann N Y Acad Sci 1142:58–71PubMedCrossRef Kira J (2008) Neuromyelitis optica and Asian phenotype of multiple sclerosis. Ann N Y Acad Sci 1142:58–71PubMedCrossRef
42.
go back to reference Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125(Pt 7):1450–1461PubMedCrossRef Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125(Pt 7):1450–1461PubMedCrossRef
43.
go back to reference Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, Lucchinetti CF (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130(Pt 5):1194–1205. doi:10.1093/brain/awl371 PubMedCrossRef Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, Lucchinetti CF (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130(Pt 5):1194–1205. doi:10.​1093/​brain/​awl371 PubMedCrossRef
44.
go back to reference Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, Takahashi T, Nakashima I, Takahashi H, Itoyama Y (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130(Pt 5):1224–1234. doi:10.1093/brain/awm047 PubMedCrossRef Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, Takahashi T, Nakashima I, Takahashi H, Itoyama Y (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130(Pt 5):1224–1234. doi:10.​1093/​brain/​awm047 PubMedCrossRef
45.
go back to reference Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, Lyon-Caen O, Gout O (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13(2):256–259. doi:10.1177/1352458506070732 PubMedCrossRef Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, Lyon-Caen O, Gout O (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13(2):256–259. doi:10.​1177/​1352458506070732​ PubMedCrossRef
47.
go back to reference Capobianco M, Malucchi S, di Sapio A, Gilli F, Sala A, Bottero R, Marnetto F, Doriguzzi Bozzo C, Bertolotto A (2007) Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease). Neurol Sci 28(4):209–211. doi:10.1007/s10072-007-0823-z PubMedCrossRef Capobianco M, Malucchi S, di Sapio A, Gilli F, Sala A, Bottero R, Marnetto F, Doriguzzi Bozzo C, Bertolotto A (2007) Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease). Neurol Sci 28(4):209–211. doi:10.​1007/​s10072-007-0823-z PubMedCrossRef
48.
go back to reference Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. doi:10.1001/archneurol.2011.154 Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. doi:10.​1001/​archneurol.​2011.​154
49.
go back to reference Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310–1315. doi:10.1212/WNL.0b013e3182152881 PubMedCrossRef Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310–1315. doi:10.​1212/​WNL.​0b013e3182152881​ PubMedCrossRef
52.
go back to reference Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178(10):6092–6099PubMed Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178(10):6092–6099PubMed
54.
go back to reference Shimizu Y, Yokoyama K, Misu T, Takahashi T, Fujihara K, Kikuchi S, Itoyama Y, Iwata M (2008) Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 255(2):305–307. doi:10.1007/s00415-007-0730-5 PubMedCrossRef Shimizu Y, Yokoyama K, Misu T, Takahashi T, Fujihara K, Kikuchi S, Itoyama Y, Iwata M (2008) Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 255(2):305–307. doi:10.​1007/​s00415-007-0730-5 PubMedCrossRef
55.
57.
go back to reference Transverse Myelitis Consortium Working Group (2002) Proposed diagnostic criteria, nosology of acute transverse myelitis. Neurology 59(4):499–505CrossRef Transverse Myelitis Consortium Working Group (2002) Proposed diagnostic criteria, nosology of acute transverse myelitis. Neurology 59(4):499–505CrossRef
60.
go back to reference de Seze J, Lanctin C, Lebrun C, Malikova I, Papeix C, Wiertlewski S, Pelletier J, Gout O, Clerc C, Moreau C, Defer G, Edan G, Dubas F, Vermersch P (2005) Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 65(12):1950–1953. doi:10.1212/01.wnl.0000188896.48308.26 PubMedCrossRef de Seze J, Lanctin C, Lebrun C, Malikova I, Papeix C, Wiertlewski S, Pelletier J, Gout O, Clerc C, Moreau C, Defer G, Edan G, Dubas F, Vermersch P (2005) Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 65(12):1950–1953. doi:10.​1212/​01.​wnl.​0000188896.​48308.​26 PubMedCrossRef
61.
go back to reference Bruna J, Martinez-Yelamos S, Martinez-Yelamos A, Rubio F, Arbizu T (2006) Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 12(2):169–173PubMedCrossRef Bruna J, Martinez-Yelamos S, Martinez-Yelamos A, Rubio F, Arbizu T (2006) Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 12(2):169–173PubMedCrossRef
62.
go back to reference Alvarenga MP, Thuler LC, Neto SP, Vasconcelos CC, Camargo SG, Papais-Alvarenga RM (2010) The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. J Neurol 257(6):992–998. doi:10.1007/s00415-009-5450-6 PubMedCrossRef Alvarenga MP, Thuler LC, Neto SP, Vasconcelos CC, Camargo SG, Papais-Alvarenga RM (2010) The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. J Neurol 257(6):992–998. doi:10.​1007/​s00415-009-5450-6 PubMedCrossRef
66.
go back to reference Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 116(Pt 1):135–146PubMedCrossRef Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 116(Pt 1):135–146PubMedCrossRef
67.
go back to reference Bashir K, Whitaker JN (2000) Importance of para-clinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI. Mult Scler 6(5):312–316PubMed Bashir K, Whitaker JN (2000) Importance of para-clinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI. Mult Scler 6(5):312–316PubMed
71.
go back to reference Lipton HL, Teasdall RD (1973) Acute transverse myelopathy in adults: a follow-up study. Arch Neurol 28(4):252–257PubMedCrossRef Lipton HL, Teasdall RD (1973) Acute transverse myelopathy in adults: a follow-up study. Arch Neurol 28(4):252–257PubMedCrossRef
72.
go back to reference Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, Martinez T, Drummond J, Dike S, Pletnikov M, Keswani SC, Moran TH, Pardo CA, Calabresi PA, Kerr DA (2005) IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115(10):2731–2741. doi:10.1172/JCI25141 PubMedCrossRef Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, Martinez T, Drummond J, Dike S, Pletnikov M, Keswani SC, Moran TH, Pardo CA, Calabresi PA, Kerr DA (2005) IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115(10):2731–2741. doi:10.​1172/​JCI25141 PubMedCrossRef
75.
go back to reference Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878–886PubMedCrossRef Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878–886PubMedCrossRef
77.
go back to reference Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558PubMedCrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558PubMedCrossRef
78.
go back to reference Kim SM, Waters P, Vincent A, Kim SY, Kim HJ, Hong YH, Park KS, Min JH, Sung JJ, Lee KW (2009) Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler 15(9):1062–1068. doi:10.1177/1352458509106636 PubMedCrossRef Kim SM, Waters P, Vincent A, Kim SY, Kim HJ, Hong YH, Park KS, Min JH, Sung JJ, Lee KW (2009) Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler 15(9):1062–1068. doi:10.​1177/​1352458509106636​ PubMedCrossRef
79.
go back to reference Kim SM, Waters P, Vincent A, Kim SY, Kim HJ, Hong YH, Park KS, Min JH, Sung JJ, Lee KW (2009) Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler 15(9):1062–1068PubMedCrossRef Kim SM, Waters P, Vincent A, Kim SY, Kim HJ, Hong YH, Park KS, Min JH, Sung JJ, Lee KW (2009) Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler 15(9):1062–1068PubMedCrossRef
80.
go back to reference Pericot I, Brieva L, Tintore M, Rio J, Sastre-Garriga J, Nos C, Montalban X (2003) Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis. Mult Scler 9(3):256–259PubMedCrossRef Pericot I, Brieva L, Tintore M, Rio J, Sastre-Garriga J, Nos C, Montalban X (2003) Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis. Mult Scler 9(3):256–259PubMedCrossRef
81.
go back to reference Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Dubucquoi S, Pruvo JP, Vermersch P, Hatron PY (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 83(5):280–291CrossRef Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Dubucquoi S, Pruvo JP, Vermersch P, Hatron PY (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 83(5):280–291CrossRef
82.
go back to reference Binder A, Snaith ML, Isenberg D (1988) Sjögren’s syndrome: a study of its neurological complications. Br J Rheumatol 27(4):275–280PubMedCrossRef Binder A, Snaith ML, Isenberg D (1988) Sjögren’s syndrome: a study of its neurological complications. Br J Rheumatol 27(4):275–280PubMedCrossRef
83.
go back to reference Pillemer SR, Matteson EL, Jacobsson LT, Martens PB, Melton LJ 3rd, O’Fallon WM, Fox PC (2001) Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 76(6):593–599PubMed Pillemer SR, Matteson EL, Jacobsson LT, Martens PB, Melton LJ 3rd, O’Fallon WM, Fox PC (2001) Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 76(6):593–599PubMed
84.
go back to reference Alexander EL, Malinow K, Lejewski JE, Jerdan MS, Provost TT, Alexander GE (1986) Primary Sjögren’s syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 104(3):323–330PubMed Alexander EL, Malinow K, Lejewski JE, Jerdan MS, Provost TT, Alexander GE (1986) Primary Sjögren’s syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 104(3):323–330PubMed
85.
go back to reference Williams CS, Butler E, Roman GC (2001) Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 58(5):815–819PubMedCrossRef Williams CS, Butler E, Roman GC (2001) Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 58(5):815–819PubMedCrossRef
88.
go back to reference Ellis SG, Verity MA (1979) Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 8(3):212–221PubMedCrossRef Ellis SG, Verity MA (1979) Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 8(3):212–221PubMedCrossRef
89.
go back to reference Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ (2000) Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 59(2):120–124PubMedCrossRef Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ (2000) Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 59(2):120–124PubMedCrossRef
90.
go back to reference Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30(5):985–992PubMed Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30(5):985–992PubMed
91.
go back to reference Espinosa G, Mendizabal A, Minguez S, Ramo-Tello C, Capellades J, Olive A, Cervera R (2010) Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 39(4):246–256. doi:10.1016/j.semarthrit.2008.09.002 PubMedCrossRef Espinosa G, Mendizabal A, Minguez S, Ramo-Tello C, Capellades J, Olive A, Cervera R (2010) Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 39(4):246–256. doi:10.​1016/​j.​semarthrit.​2008.​09.​002 PubMedCrossRef
92.
go back to reference Sherer Y, Hassin S, Shoenfeld Y, Levy Y, Livneh A, Ohry A, Langevitz P (2002) Transverse myelitis in patients with antiphospholipid antibodies–the importance of early diagnosis and treatment. Clin Rheumatol 21(3):207–210PubMedCrossRef Sherer Y, Hassin S, Shoenfeld Y, Levy Y, Livneh A, Ohry A, Langevitz P (2002) Transverse myelitis in patients with antiphospholipid antibodies–the importance of early diagnosis and treatment. Clin Rheumatol 21(3):207–210PubMedCrossRef
94.
go back to reference Creamer P, Kirwan J (1992) Seronegative systemic lupus erythematosus. Br J Rheumatol 31(9):619–622PubMedCrossRef Creamer P, Kirwan J (1992) Seronegative systemic lupus erythematosus. Br J Rheumatol 31(9):619–622PubMedCrossRef
96.
go back to reference Propper DJ, Bucknall RC (1989) Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis 48(6):512–515PubMedCrossRef Propper DJ, Bucknall RC (1989) Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis 48(6):512–515PubMedCrossRef
97.
go back to reference Appenzeller S, Vasconcelos Faria A, Li LM, Costallat LT, Cendes F (2008) Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 64(6):635–643. doi:10.1002/ana.21483 PubMedCrossRef Appenzeller S, Vasconcelos Faria A, Li LM, Costallat LT, Cendes F (2008) Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 64(6):635–643. doi:10.​1002/​ana.​21483 PubMedCrossRef
98.
99.
go back to reference Boumpas DT, Patronas NJ, Dalakas MC, Hakim CA, Klippel JH, Balow JE (1990) Acute transverse myelitis in systemic lupus erythematosus: magnetic resonance imaging and review of the literature. J Rheumatol 17(1):89–92PubMed Boumpas DT, Patronas NJ, Dalakas MC, Hakim CA, Klippel JH, Balow JE (1990) Acute transverse myelitis in systemic lupus erythematosus: magnetic resonance imaging and review of the literature. J Rheumatol 17(1):89–92PubMed
100.
go back to reference Salmaggi A, Lamperti E, Eoli M, Venegoni E, Bruzzone MG, Riccio G, La Mantia L (1994) Spinal cord involvement and systemic lupus erythematosus: clinical and magnetic resonance findings in 5 patients. Clin Exp Rheumatol 12(4):389–394PubMed Salmaggi A, Lamperti E, Eoli M, Venegoni E, Bruzzone MG, Riccio G, La Mantia L (1994) Spinal cord involvement and systemic lupus erythematosus: clinical and magnetic resonance findings in 5 patients. Clin Exp Rheumatol 12(4):389–394PubMed
101.
go back to reference Trevisani VF, Castro AA, Neves Neto JF, Atallah AN (2006) Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2:CD002265. doi:10.1002/14651858.CD002265.pub2 PubMed Trevisani VF, Castro AA, Neves Neto JF, Atallah AN (2006) Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2:CD002265. doi:10.​1002/​14651858.​CD002265.​pub2 PubMed
102.
go back to reference Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, Fuentes de la Mata J, Clark P, Vargas F, Alocer-Varela J (2005) Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 64(4):620–625. doi:10.1136/ard.2004.025528 PubMedCrossRef Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, Fuentes de la Mata J, Clark P, Vargas F, Alocer-Varela J (2005) Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 64(4):620–625. doi:10.​1136/​ard.​2004.​025528 PubMedCrossRef
103.
go back to reference Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M (2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59(12):1796–1804. doi:10.1002/art.24068 PubMedCrossRef Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M (2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59(12):1796–1804. doi:10.​1002/​art.​24068 PubMedCrossRef
104.
go back to reference Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR (2007) Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2(5):968–975. doi:10.2215/CJN.01200307 PubMedCrossRef Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR (2007) Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2(5):968–975. doi:10.​2215/​CJN.​01200307 PubMedCrossRef
105.
go back to reference Perry A, Vuitch F (1995) Causes of death in patients with sarcoidosis: a morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 119(2):167–172PubMed Perry A, Vuitch F (1995) Causes of death in patients with sarcoidosis: a morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 119(2):167–172PubMed
106.
go back to reference Chapelon-Abric C (2001) Neurosarcoidosis. Ann Med Interne (Paris) 152(2):113–124 Chapelon-Abric C (2001) Neurosarcoidosis. Ann Med Interne (Paris) 152(2):113–124
107.
108.
go back to reference Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145(3):234–241PubMedCrossRef Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145(3):234–241PubMedCrossRef
110.
go back to reference Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, Scadding JW, Thompson EJ, Chamoun V, Miller DH, McDonald WI, Mitchell D (1999) Central nervous system sarcoidosis–diagnosis and management. Qjm 92(2):103–117PubMedCrossRef Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, Scadding JW, Thompson EJ, Chamoun V, Miller DH, McDonald WI, Mitchell D (1999) Central nervous system sarcoidosis–diagnosis and management. Qjm 92(2):103–117PubMedCrossRef
113.
go back to reference Stern BJ, Krumholz A, Johns C, Scott P, Nissim J (1985) Sarcoidosis and its neurological manifestations. Arch Neurol 42(9):909–917PubMedCrossRef Stern BJ, Krumholz A, Johns C, Scott P, Nissim J (1985) Sarcoidosis and its neurological manifestations. Arch Neurol 42(9):909–917PubMedCrossRef
114.
go back to reference Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, Amoura Z, Chalpelon-Abric C, Lyon-Caen O, Valeyre D, Piette JC (2010) Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 89(2):133–140CrossRef Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, Amoura Z, Chalpelon-Abric C, Lyon-Caen O, Valeyre D, Piette JC (2010) Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 89(2):133–140CrossRef
115.
go back to reference Dale JC, O’Brien JF (1999) Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc 74(5):535PubMed Dale JC, O’Brien JF (1999) Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc 74(5):535PubMed
116.
go back to reference Baughman RP, Iannuzzi MC (2000) Diagnosis of sarcoidosis: when is a peek good enough? Chest 117(4):931–932PubMedCrossRef Baughman RP, Iannuzzi MC (2000) Diagnosis of sarcoidosis: when is a peek good enough? Chest 117(4):931–932PubMedCrossRef
117.
go back to reference Kouba DJ, Mimouni D, Rencic A, Nousari HC (2003) Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 148(1):147–148PubMedCrossRef Kouba DJ, Mimouni D, Rencic A, Nousari HC (2003) Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 148(1):147–148PubMedCrossRef
118.
go back to reference Doty JD, Mazur JE, Judson MA (2003) Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 124(5):2023–2026PubMedCrossRef Doty JD, Mazur JE, Judson MA (2003) Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 124(5):2023–2026PubMedCrossRef
119.
go back to reference Carter JD, Valeriano J, Vasey FB, Bognar B (2004) Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 117(4):277–279PubMedCrossRef Carter JD, Valeriano J, Vasey FB, Bognar B (2004) Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 117(4):277–279PubMedCrossRef
120.
go back to reference Duna GF, Calabrese LH (1995) Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system. J Rheumatol 22(4):662–667PubMed Duna GF, Calabrese LH (1995) Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system. J Rheumatol 22(4):662–667PubMed
121.
go back to reference International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335(8697):1078–1080 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335(8697):1078–1080
122.
123.
go back to reference Siva A, Altintas A, Saip S (2004) Behçet’s syndrome and the nervous system. Curr Opin Neurol 17(3):347–357PubMedCrossRef Siva A, Altintas A, Saip S (2004) Behçet’s syndrome and the nervous system. Curr Opin Neurol 17(3):347–357PubMedCrossRef
124.
go back to reference Al-Araji A, Kidd DP (2009) Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8(2):192–204PubMedCrossRef Al-Araji A, Kidd DP (2009) Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8(2):192–204PubMedCrossRef
125.
126.
go back to reference Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients: the Neuro-Behçet study group. Brain 122(Pt 11):2171–2182PubMedCrossRef Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients: the Neuro-Behçet study group. Brain 122(Pt 11):2171–2182PubMedCrossRef
127.
128.
go back to reference Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behçet’s syndrome. Brain 122(Pt 11):2183–2194PubMedCrossRef Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behçet’s syndrome. Brain 122(Pt 11):2183–2194PubMedCrossRef
129.
go back to reference Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P (2003) Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 145(1–2):127–134PubMedCrossRef Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P (2003) Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 145(1–2):127–134PubMedCrossRef
130.
go back to reference Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3(3):148–155PubMedCrossRef Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3(3):148–155PubMedCrossRef
131.
go back to reference Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, Kocer N, Yazici H (2001) Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248(2):95–103PubMedCrossRef Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, Kocer N, Yazici H (2001) Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248(2):95–103PubMedCrossRef
132.
go back to reference Kocer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, Hamuryudan V (1999) CNS involvement in neuro-Behçet syndrome: an MR study. AJNR Am J Neuroradiol 20(6):1015–1024PubMed Kocer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, Hamuryudan V (1999) CNS involvement in neuro-Behçet syndrome: an MR study. AJNR Am J Neuroradiol 20(6):1015–1024PubMed
133.
go back to reference Yesilot N, Mutlu M, Gungor O, Baykal B, Serdaroglu P, Akman-Demir G (2007) Clinical characteristics and course of spinal cord involvement in Behçet’s disease. Eur J Neurol 14(7):729–737PubMedCrossRef Yesilot N, Mutlu M, Gungor O, Baykal B, Serdaroglu P, Akman-Demir G (2007) Clinical characteristics and course of spinal cord involvement in Behçet’s disease. Eur J Neurol 14(7):729–737PubMedCrossRef
134.
go back to reference Kidd D, Beynon HL (2003) The neurological complications of systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 20(2):85–94PubMed Kidd D, Beynon HL (2003) The neurological complications of systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 20(2):85–94PubMed
135.
go back to reference Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behçet’s syndrome. J Neurol Sci 272(1–2):99–105PubMedCrossRef Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behçet’s syndrome. J Neurol Sci 272(1–2):99–105PubMedCrossRef
136.
137.
go back to reference Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Weigand SD, Miller DV, Giannini C, Meschia JF, Huston J 3rd, Hunder GG (2007) Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 62(5):442–451PubMedCrossRef Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Weigand SD, Miller DV, Giannini C, Meschia JF, Huston J 3rd, Hunder GG (2007) Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 62(5):442–451PubMedCrossRef
138.
go back to reference Benseler S, Schneider R (2004) Central nervous system vasculitis in children. Curr Opin Rheumatol 16(1):43–50PubMedCrossRef Benseler S, Schneider R (2004) Central nervous system vasculitis in children. Curr Opin Rheumatol 16(1):43–50PubMedCrossRef
140.
go back to reference Calabrese LH, Duna GF, Lie JT (1997) Vasculitis in the central nervous system. Arthritis Rheum 40(7):1189–1201PubMed Calabrese LH, Duna GF, Lie JT (1997) Vasculitis in the central nervous system. Arthritis Rheum 40(7):1189–1201PubMed
141.
go back to reference Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Huston J 3rd, Meschia JF, Giannini C, Miller DV, Hunder GG (2008) Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy. Rheumatology (Oxford) 47(11):1671–1677CrossRef Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Huston J 3rd, Meschia JF, Giannini C, Miller DV, Hunder GG (2008) Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy. Rheumatology (Oxford) 47(11):1671–1677CrossRef
142.
go back to reference Lie JT (1992) Primary (granulomatous) angiitis of the central nervous system: a clinicopathologic analysis of 15 new cases and a review of the literature. Hum Pathol 23(2):164–171PubMedCrossRef Lie JT (1992) Primary (granulomatous) angiitis of the central nervous system: a clinicopathologic analysis of 15 new cases and a review of the literature. Hum Pathol 23(2):164–171PubMedCrossRef
143.
go back to reference Pomper MG, Miller TJ, Stone JH, Tidmore WC, Hellmann DB (1999) CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. AJNR Am J Neuroradiol 20(1):75–85PubMed Pomper MG, Miller TJ, Stone JH, Tidmore WC, Hellmann DB (1999) CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. AJNR Am J Neuroradiol 20(1):75–85PubMed
144.
go back to reference Harris KG, Tran DD, Sickels WJ, Cornell SH, Yuh WT (1994) Diagnosing intracranial vasculitis: the roles of MR and angiography. AJNR Am J Neuroradiol 15(2):317–330PubMed Harris KG, Tran DD, Sickels WJ, Cornell SH, Yuh WT (1994) Diagnosing intracranial vasculitis: the roles of MR and angiography. AJNR Am J Neuroradiol 15(2):317–330PubMed
145.
go back to reference Calabrese LH (2003) Clinical management issues in vasculitis: angiographically defined angiitis of the central nervous system—diagnostic and therapeutic dilemmas. Clin Exp Rheumatol 21(6 Suppl 32):S127–S130PubMed Calabrese LH (2003) Clinical management issues in vasculitis: angiographically defined angiitis of the central nervous system—diagnostic and therapeutic dilemmas. Clin Exp Rheumatol 21(6 Suppl 32):S127–S130PubMed
146.
go back to reference Vollmer TL, Guarnaccia J, Harrington W, Pacia SV, Petroff OA (1993) Idiopathic granulomatous angiitis of the central nervous system: diagnostic challenges. Arch Neurol 50(9):925–930PubMedCrossRef Vollmer TL, Guarnaccia J, Harrington W, Pacia SV, Petroff OA (1993) Idiopathic granulomatous angiitis of the central nervous system: diagnostic challenges. Arch Neurol 50(9):925–930PubMedCrossRef
147.
go back to reference Birnbaum J, Hellmann DB (2009) Primary angiitis of the central nervous system. Arch Neurol 66(6):704–709PubMedCrossRef Birnbaum J, Hellmann DB (2009) Primary angiitis of the central nervous system. Arch Neurol 66(6):704–709PubMedCrossRef
148.
go back to reference Levy JA, Shimabukuro J, Hollander H, Mills J, Kaminsky L (1985) Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet 2(8455):586–588PubMed Levy JA, Shimabukuro J, Hollander H, Mills J, Kaminsky L (1985) Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet 2(8455):586–588PubMed
Metadata
Title
A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis
Authors
Christopher Eckstein
Shiv Saidha
Michael Levy
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 5/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-011-6240-5

Other articles of this Issue 5/2012

Journal of Neurology 5/2012 Go to the issue